NDA 020221 · Legacy
Ethyol
Amifostine · Injection
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jul 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 8, 1995
Approved uses
3
Original approval plus efficacy supplements
Registered trials
83
8 Phase 3, 1 recruiting
FAERS reports
810
726 serious, 88 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2026.
ETHYOL is a cytoprotective agent indicated for: – reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. ( 1.1 ) – reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. ( 1.2 ) Limitation of Use Avoid the use of ETHYOL in settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy. ( 1 , 5.1 , 5.2 ) 1.1 Reduction of Cumulative Renal Toxicity with Chemotherapy ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer [see Clinical Studies (14.1) ] . 1.2 Reduction of Moderate to Severe Xerostomia from Radiation of the Head and Neck ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands [see Clinical Studies (14.2) ] . Limitation of Use Do not use ETHYOL in other settings where chemotherapy can produce a significant survival benefit or cure [see Warnings and Precautions (5.1) ] , or in patients receiving definitive radiotherapy [see Warnings and Precautions (5.2) ] , except in the context of a clinical study.
Mechanism: ETHYOL is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. The ability of ETHYOL to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 1999 Supplement 12 · Efficacy · priority review ReviewLetterLabel
- Mar 15, 1996 Supplement 2 · Efficacy
- Dec 8, 1995 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
- ETHYOL · AMIFOSTINE 500MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- ETHYOL · AMIFOSTINE 375MG/VIAL · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Amifostine" as an intervention, any sponsor and status, largest first.
- Subcutaneous Amifostine Safety StudyCompleted
Mt. Sinai Medical Center, MiamiAcademic, hospital or other
NCT00158041 · 452 participants · Start Jan 2002
Drug: Amifostine administered subcutaneously · For: Head and Neck Cancer; Lung Cancer; Lymphoma
Sites: Miami Beach, Florida
- A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine RegimensPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT01762514 · 360 participants (planned) · Start Jan 2013 · Primary completion Jun 2019
Drug: Amifostine every-other-day regimen; Amifostine everyday regimen · For: Nasopharyngeal Neoplasms; Salivary Gland Diseases; Bone Marrow Diseases and 1 more
Sites: Guangzhou, China · 7 sites in all
- Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck CarcinomasPivotal-lookingCompleted
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT00158691 · 296 participants · Start Mar 2001
Drug: Ethyol · For: Head and Neck Cancer
Sites: Nantes, France
- Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00003994 · 277 participants · Start Mar 1999 · Primary completion Oct 2007
Drug: cisplatin; vincristine sulfate and 3 more · For: Childhood Hepatoblastoma; Recurrent Childhood Liver Cancer; Stage I Childhood Liver Cancer
Sites: Arcadia, California
- A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast CancerPivotal-lookingActive, not recruiting
Graegis Pharmaceuticals LtdIndustry
NCT07192588 · 273 participants (planned) · Start Jul 26, 2024 · Primary completion Sep 30, 2026
Drug: GR1014-CG 2.4%; Vehicle Gel and 1 more · For: Radiodermatitis; Acute
Sites: Bordeaux, France; Lyon, France; Villejuif, France · 4 sites in all
- Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00003313 · 243 participants · Start Sep 1998 · Primary completion Jul 2002
Drug: filgrastim; amifostine trihydrate and 2 more · For: Drug/Agent Toxicity by Tissue/Organ; Lung Cancer; Oral Complications and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 264 sites in all
- Radiation-protection Effect of Amifostine in Locally Advanced Rectal CancerPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT03702985 · 160 participants (planned) · Start May 28, 2018 · Primary completion Nov 1, 2019
Drug: Capecitabine; Irinotecan and 1 more · For: Locally Advanced Rectal Cancer
Sites: Shanghai, China
Brigham and Women's HospitalAcademic, hospital or other
NCT00571298 · 141 participants · Start Nov 2007 · Primary completion Nov 2011
Drug: Cisplatin; gemcitabine and 2 more · For: Malignant Pleural Mesothelioma
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia159
- nausea142
- vomiting115
- hypotension110
- mucosal inflammation91
- chills69
- dehydration69
- rash66
- pruritus57
- rash generalised51
- thrombocytopenia51
- dyspnoea50
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 106 |
| 2005 | 141 |
| 2006 | 150 |
| 2007 | 90 |
| 2008 | 46 |
| 2009 | 22 |
| 2010 | 11 |
| 2011 | 28 |
| 2012 | 18 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 14 |
| 2016 | 58 |
| 2017 | 24 |
| 2018 | 19 |
| 2019 | 13 |
| 2020 | 5 |
| 2021 | 13 |
| 2022 | 8 |
| 2023 | 16 |
| 2024 | 3 |
| 2025 | 13 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of salivary gland hypofunction and/or xerostomia induced by non-surgical cancer therapies: prevention strategies.
Mercadante V, Smith DK, Abdalla-Aslan R, et al. · Support Care Cancer 2025 · Systematic Review
- Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC, Caron HN, Dickinson HO, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials.
Auttara-Atthakorn A, Sungmala J, Anothaisintawee T, et al. · Front Endocrinol (Lausanne) 2022 · Systematic Review
- Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ, Lange BJ, Needle MN, et al. · Pediatr Blood Cancer 2004 · Clinical Trial
- Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Ma C, Xie J, Chen Q, et al. · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
- Interventions for preventing oral mucositis for patients with cancer receiving treatment.
Worthington HV, Clarkson JE, Bryan G, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.